




SEA-CD70

An investigational sugar-engineered antibody directed to CD70



Key Attributes

- Humanized, nonfucosylated IgG1 monoclonal antibody¹
- Increased affinity for activating FcγRIIIa and minimal affinity for inhibitory FcγRIIb¹
- Binding to FcγRIIIa confers enhanced Fc-mediated effector function¹

Target: CD70

- A cell surface ligand of CD27²⁻⁴
- Expressed on AML and MDS malignant blasts and leukemic blasts that propagate the disease^{1,5-8}
- Limited expression by normal cells²⁻⁶

Proposed Mechanism of Action^{1,a}


- Enhanced antibody-dependent cellular cytotoxicity
- Blockade of CD70/CD27-mediated proliferative signaling in malignant blast cells
- Antibody-dependent cellular phagocytosis
- Complement-dependent cytotoxicity

AML: acute myeloid leukemia; **CD:** cluster of differentiation; **IgG1:** immunoglobulin G1; **MDS:** myelodysplastic syndrome


^aBased on preclinical data

1. Diolaiti D. Blood. 2020; 23. 2. Grewal IS. Expert Opin Ther Targets. 2008; 341-51. 3. Aftimos P. Clin Cancer Res. 2017; 6411-20. 4. Cuesta-Mateos C. Front Immunol. 2018; 1936. 5. Schurch CM. Front Oncol. 2018; 152. 6. Riether C. J Exp Med. 2017; 359-80. 7. Syed K. Stem Cell Res Ther. 2020; 132. 8. Riether C. Nat Med. 2020; 1459-67.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Proposed Mechanism of Action^{1,a}



ADCC: antibody-dependent cellular cytotoxicity; **ADCP:** antibody-dependent cellular phagocytosis; **CD:** cluster of differentiation; **CDC:** complement-dependent cytotoxicity; **MAC:** membrane attack complex; **NK:** natural killer

^aBased on preclinical data

1. Diolaiti D. Blood. 2020: 23.

Clinical Trials



RECRUITING

SGNS70-101: Myelodysplastic syndrome and acute myeloid leukemia (NCT04227847) SEA-CD70

Phase 1

Phase 2

Phase 3

Clinical trial information retrieved from clinicaltrials.gov, accessed Oct 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.